COLUMVI⢠(glofitamab-gxbm) after at least 2 courses of therapy for certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL)
Description
After at least 2 courses of therapy in certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL), a new bispecific antibody treatment is available: COLUMVI⢠(glofitamab-gxbm). See important safety including Serious Side Effects for more information.